Talon B, Perez A, Yan C, Alobaidi A, Zhang KH, Schultz BG, Suda KJ, Touchette DR. Economic evaluations of clinical pharmacy services in the United States: 2011-2017. J Am Coll Clin Pharm. 2020 Jun;3(4):793-806. doi: 10.1002/jac5.1199
Wilburn J, Twiss J, Kemp K, McKenna SP. A qualitative study of the impact of Crohn's disease from a patient's perspective. Frontline Gastroenterol. 2017;8:68-73. doi: 10.1136/flgastro-2015-100678
Meyers JL, Parasuraman S, Bell K, Graham JP, Candrilli SD. The high-cost, type 2 diabetes mellitus patient: an analysis of managed care administrative data. Arch Public Health. 2014 Feb 27;72(1):6.
Doward LC, Wilburn J, McKenna SP, Leicester R, Epstein O, Hedley V, Korala S, Twiss J, Jones D, Geraint M. Development and validation of the Bowel Cleansing Impact Review (BOCLIR). Frontline Gastroenterol. 2013 Feb;4(2):112-9. doi: 10.1136/flgastro-2012-100278
Davis KL, Misurski D, Miller J, Karve S. Cost impact of complications in meningococcal disease evidence from a United States managed care population. Hum Vacci. 2011 Apr 1;7(4):458-65.
Davis KL, Misurski D, Miller JM, Bell TJ, Bapat B. Cost of acute hospitalization and post-discharge follow-up care for meningococcal disease in the US. Hum Vacci. 2011 Jan 1;7(1):96-101.
Earnshaw SR, Wilson M, Joshi AV. The effect of recombinant activated factor VII in the treatment of intracerebral hemorrhage on health plan budgets. Managed Care Interface. 2007 Jan 1;19(11):39-45.
Earnshaw SR, Wilson MR, Joshi AV. Health plan budget impact analysis of recombinant activated factor VII (rFVIIa) in the treatment of intracerebral hemorrhage. Managed Care Interface. 2006;19(11):39-45.
Earnshaw SR, Candrilli SD, Fernandes AW, Higashi MK. A cost-effectiveness analysis of antibiotic therapy in macrolide-resistant community-acquired pneumonia. Managed Care Interface. 2005 Oct 1;18(10):36-44.